HiFiBiO Therapeutics

Reminder to stop by our two posters at #ESMO2024! HiFiBiO Therapeutics will present interim Phase 1 clinical data for two novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 and a best-in-class BTLA antagonist HFB200603.?These programs have shown promise both as monotherapy and in combination with anti-PD-1, demonstrating the capability to elicit a robust anti-cancer immune response, even in IO refractory tumors.? ? Link to press release and abstract: https://lnkd.in/eFgCHPxJ? ? #cancer #immunotherapy #innovation?

Reminder to stop by our two posters at #ESMO2024! HiFiBiO Therapeutics will present interim Phase 1 clinical data for two novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 and a best-in-class BTLA antagonist HFB200603.?These programs have shown promise both as monotherapy and in combination with anti-PD-1, demonstrating the capability to elicit a robust anti-cancer immune response, even in IO refractory tumors.? ? Link to press release and abstract: https://lnkd.in/eFgCHPxJ? ? #cancer #immunotherapy #innovation?

HiFiBiO Therapeutics, a leading clinical stage immune modulation company, announced today its participation in the #ESMO2024 meeting, taking place Sep 13-17 in Barcelona, Spain. On Saturday, September 14, the company will present compelling Phase 1 trial data for two novel monoclonal antibodies: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).? ? Come visit our posters to learn more about these two programs and their therapeutic potential in IO refractory tumors! View full press release here: https://lnkd.in/eFgCHPxJ ? #cancer #aiandml #immunooncology #immunotherapy #innovation ?

We are thrilled that HiFiBiO Therapeutics has been recognized as a Finalist for the Start-up of the Year Award, and its CEO, Liang Schweizer, has been selected as a Finalist for the Lifetime Achievement Award at #BiotechWeekBoston!?? Under Liang’s leadership, our passionate team has advanced a diverse portfolio of best-in-class and first-in-class immunotherapies, including three novel IO programs into Phase I. Furthermore, our single-cell and AI/ML powered Drug Intelligence Science (DIS?) translational platform provides unique, high resolution insights into patient immunobiology and disease mechanisms to maximize clinical benefit.?? #biotech #immunotherapy #innovation #DrugIntelligenceScience??

We are excited to welcome Carl Liederman to our Board of Directors! Carl is a prominent leader in Corporate and Legal Strategy with over 30 years of experience in VC, Cross-border M&A, PE, Capital Markets, Healthcare (Pharma, Medtech, and Biotech),?and Impact and Sustainability. His deep experience will bring tremendous value as we continue our journey as a leading immune modulation biotech.

Proud to have our CEO Liang Schweizer selected as a winner in the Entrepreneur Of The Year? New England program!?She joins an esteemed multi-industry community of other entrepreneurs who have driven their companies’ success, transformed their industries, and made a positive impact on their employees and communities! https://lnkd.in/eJ3BhqJS #EOYUS #EOYNE

June is #NationalCancerSurvivorMonth. Join HiFiBiO Therapeutics in honoring the over 18 million individuals in the U.S. living with a history of cancer and the unique challenges they continue to face (AACR https://lnkd.in/g-p7KKU). Thanks to remarkable advances in cancer research, there have been significant improvements in cancer diagnostics and treatment, particularly in the field of cancer immunotherapies. However, substantial gaps remain. Many patients harbor cancers that either do not respond to current standard immunotherapies or experience relapse, limiting the potential benefits (https://lnkd.in/ezt2uiyf). HiFiBiO Therapeutics is utilizing its DIS? translational platform to develop a pipeline of novel immune modulatory therapeutics aimed at overcoming these gaps. The company has advanced three cancer immunotherapies into Phase I trials, showing promising developments: the first-in-class anti-TNFR2 antibody HFB200301 (clinical trial NCT05238883), the next-generation OX40 agonist antibody HFB301001 (clinical trial NCT05229601), and the best-in-class BTLA antagonist antibody HFB200603 (clinical trial NCT05789069).? ? #hifibioway #cancer #cancerawareness #cancertreatment #cancersurvivor #innovation #immunotherapy?

Congratulations to our partner FibroGen, Inc. for receiving FDA clearance for FG-3165, a Gal-9 antagonist derived from HiFiBiO's HFB200902! ? HiFiBiO Therapeutics embraces an open innovation model where our team works collaboratively with our partners globally to accelerate advances in immunotherapies. We are attending BIO if you are interested in exploring partnership opportunities! #openinnovation #immunotherapies #partnership

There was amazing buzz around our two posters at #ASCO2024! Our team enjoyed the exciting discussions around the?results of our two Ph1 clinical trials for HFB200301, a best-in-class TNFR2 agonist and HFB301001, a next-generation OX40 agonist.? ? The e-posters are now up on our website for viewing. ? HFB200301: https://lnkd.in/dPQmsECv ? HFB301001: https://lnkd.in/deGb_wpH

Meet HiFiBiO's Timothy Miller at the upcoming #BIO2024 International Convention on June 3rd to 6th?in San Diego, CA. Looking forward?to connect and collaborate with fellow biotech and pharma leaders!